Orange Book product · Generic (ANDA)
ABACAVIR SULFATE AND LAMIVUDINE
ABACAVIR SULFATE; LAMIVUDINE
At a glance
Dec 19, 2024
Approved
Generic (ANDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Dec 19, 2024
1 yr 6 mo ago
Today
Pharmaceutical detail
Active ingredient
ABACAVIR SULFATE; LAMIVUDINE
Strength
EQ 600MG BASE;300MG
Dosage form
TABLET
Route
ORAL
TE code
Not listed
Application
ANDA 212663
Product number
001
Marketing status
DISCN
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of ABACAVIR SULFATE; LAMIVUDINE
- 2023ABACAVIR SULFATE AND LAMIVUDINEBrand (NDA)
NDA 204311 · PHARMOBEDIENT
- 2004EPZICOMBrand (NDA)
NDA 021652 · VIIV HLTHCARE
- 2025ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 205412 · HETERO LABS LTD V
- 2022ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 216332 · LAURUS
- 2018ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 090159 · AUROBINDO PHARMA LTD
- 2018ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 208990 · ZYDUS PHARMS
- 2017ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 206151 · AUROBINDO PHARMA
- 2017ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 204990 · CHARTWELL RX
- 2017ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 091144 · CIPLA
- 2016ABACAVIR SULFATE AND LAMIVUDINEGeneric (ANDA)
ANDA 079246 · TEVA PHARMS USA
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
